Arthneeti
All Q2 FY27 results →
AH

Anlon Healthcare Ltd

Q2 FY27Pharmaceuticals & Biotechnology

Anlon Healthcare Q2 Results 2026 (FY27) investor presentation: Revenue & Margins

Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.

Price₹26
Market cap₹1.4K Cr
P/E43.5
Updated30 Oct 2026
Read3 min read

Anlon Healthcare Ltd Q2 FY27 key numbers

Revenue
Q2 FY27 Revenue from Operations: INR 10,561.0 Lacs.

As stated in Anlon Healthcare Ltd's Q2 FY27 investor presentation · published 16 Oct 2026. Reported figures, not investment advice.

Based on Anlon Healthcare Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

The short version

Q2 FY27 Revenue from Operations: INR 10,561.0 Lacs - Q2 FY26 Revenue from Operations: INR 5,220.1 Lacs - Year-on-Year (YoY) Revenue Growth: +102.3% - Q2 FY27 EBITDA: INR 2,524.1 Lacs (84.1% YoY increase) - Q2 FY27 Profit After Tax (PAT): INR 1,717.8 Lacs (84.4% YoY increase) - Half Year (H1) FY27 Revenue: INR 19,317.2 Lacs (125.9% increase versus H1 FY26) - Quarterly EBITDA (Q2 FY27): INR 2,524.1 Lacs, up 84.1% YoY from INR 1,371.0 Lacs in Q2 FY26 - Quarterly EBITDA Margin (Q2 FY27): 23.9% (vs.

From Anlon Healthcare Ltd's Q2 FY27 earnings-call transcript · updated 30 Oct 2026.

Revenue & Sales Performance

  • Q2 FY27 Revenue from Operations: INR 10,561.0 Lacs
  • Q2 FY26 Revenue from Operations: INR 5,220.1 Lacs
  • Year-on-Year (YoY) Revenue Growth: +102.3%
  • Q2 FY27 EBITDA: INR 2,524.1 Lacs (84.1% YoY increase)
  • Q2 FY27 Profit After Tax (PAT): INR 1,717.8 Lacs (84.4% YoY increase)

2 more points from Anlon Healthcare Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Anlon Healthcare Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Apiqo Organics: Established manufacturing platform for pharmaceutical intermediates and industrial/fine chemicals; Installed capacity 700-800 MTPA; positioned for scalable, resilient long-term growth via raw-material integration (Page 26).
  • Bizotic Lifescience: Ready-to-operate manufacturing facility for organic and inorganic products; Installed capacity 300-400 MTPA; strengthens regulatory readiness for domestic API markets (Page 26).
  • Anlon Medicos: Manufacturing finished pharmaceutical formulations (tablets, capsules); Installed capacity 500-600 MTPA; operational synergies for scalability (Page 26).
  • Upcoming capacity expansions:
  • ~1,200 MTPA Anlon installed capacity planned (Page 9).

2 more points from Anlon Healthcare Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Anlon Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Anlon Healthcare Ltd said on order book & pipeline — free account, 30 seconds.

Anlon Healthcare Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹106 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Anlon Healthcare Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Accretion Pharmaceuticals Ltd (Q2 FY27)

    25.85% increase) . Key results statement takeaways from Accretion Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Sigachi Industries Ltd (Q2 FY27)

    Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation

  • Advanced Enzyme Technologies Ltd (Q2 FY27)

    Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Key investor presentation takeaways from Advanced Enzym

  • IOL Chemicals (Q2 FY27)

    Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Key investor presentation takeaways from IOL

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Anlon Healthcare Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Anlon Healthcare Ltd Q2 FY27 results?

Q2 FY27 Revenue from Operations: INR 10,561.0 Lacs - Q2 FY26 Revenue from Operations: INR 5,220.1 Lacs - Year-on-Year (YoY) Revenue Growth: +102.3% - Q2 FY27 EBITDA: INR 2,524.1 Lacs (84.1% YoY increase) - Q2 FY27 Profit After Tax (PAT): INR 1,717.8 Lacs (84.4% YoY increase) - Half Year (H1) FY27 Revenue: INR 19,317.2 Lacs (125.9% increase versus H1 FY26) - Quarterly EBITDA (Q2 FY27): INR 2,524.1 Lacs, up 84.1% YoY from INR 1,371.0 Lacs in Q2 FY26 - Quarterly EBITDA Margin (Q2 FY27): 23.9% (vs.

What is Anlon Healthcare Ltd share price analysis?

Anlon Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 43.5 with a market cap of ₹1,376 Cr. Investors should review the full earnings analysis for detailed insights.

Is Anlon Healthcare Ltd planning capital expenditure?

Apiqo Organics: Established manufacturing platform for pharmaceutical intermediates and industrial/fine chemicals; Installed capacity 700-800 MTPA; positioned for scalable, resilient long-term growth via raw-material integration (Page 26).

Keep Anlon Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.